Iterum Therapeutics (NASDAQ:ITRM – Get Free Report) is one of 896 publicly-traded companies in the “Pharmaceuticals” industry, but how does it compare to its rivals? We will compare Iterum Therapeutics to related businesses based on the strength of its valuation, institutional ownership, profitability, risk, dividends, analyst recommendations and earnings.
Analyst Ratings
This is a summary of recent ratings and target prices for Iterum Therapeutics and its rivals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Iterum Therapeutics | 1 | 2 | 0 | 0 | 1.67 |
| Iterum Therapeutics Competitors | 7792 | 13886 | 25778 | 1037 | 2.41 |
As a group, “Pharmaceuticals” companies have a potential upside of 25.65%. Given Iterum Therapeutics’ rivals stronger consensus rating and higher possible upside, analysts clearly believe Iterum Therapeutics has less favorable growth aspects than its rivals.
Valuation & Earnings
This table compares Iterum Therapeutics and its rivals revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Iterum Therapeutics | $390,000.00 | -$24.77 million | -0.04 |
| Iterum Therapeutics Competitors | $3.54 billion | $3.17 billion | 554.50 |
Iterum Therapeutics’ rivals have higher revenue and earnings than Iterum Therapeutics. Iterum Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Institutional and Insider Ownership
9.2% of Iterum Therapeutics shares are owned by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 2.0% of Iterum Therapeutics shares are owned by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Profitability
This table compares Iterum Therapeutics and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Iterum Therapeutics | N/A | N/A | -65.54% |
| Iterum Therapeutics Competitors | -2,372.59% | -220.82% | -15.99% |
Volatility & Risk
Iterum Therapeutics has a beta of 2.96, indicating that its share price is 196% more volatile than the S&P 500. Comparatively, Iterum Therapeutics’ rivals have a beta of -4.04, indicating that their average share price is 504% less volatile than the S&P 500.
Summary
Iterum Therapeutics rivals beat Iterum Therapeutics on 10 of the 13 factors compared.
Iterum Therapeutics Company Profile
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
